433 related articles for article (PubMed ID: 27436022)
1. The added value of
Kazmierczak PM; Rominger A; Wenter V; Spitzweg C; Auernhammer C; Angele MK; Rist C; Cyran CC
Eur Radiol; 2017 Apr; 27(4):1676-1684. PubMed ID: 27436022
[TBL] [Abstract][Full Text] [Related]
2. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.
Prasad V; Ambrosini V; Hommann M; Hoersch D; Fanti S; Baum RP
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):67-77. PubMed ID: 19618183
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
[TBL] [Abstract][Full Text] [Related]
4. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
Haug A; Auernhammer CJ; Wängler B; Tiling R; Schmidt G; Göke B; Bartenstein P; Pöpperl G
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):765-70. PubMed ID: 19137293
[TBL] [Abstract][Full Text] [Related]
5. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
9. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
[TBL] [Abstract][Full Text] [Related]
10. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.
Ambrosini V; Nanni C; Zompatori M; Campana D; Tomassetti P; Castellucci P; Allegri V; Rubello D; Montini G; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):722-7. PubMed ID: 20107793
[TBL] [Abstract][Full Text] [Related]
11. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
Putzer D; Kroiss A; Waitz D; Gabriel M; Traub-Weidinger T; Uprimny C; von Guggenberg E; Decristoforo C; Warwitz B; Widmann G; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
[TBL] [Abstract][Full Text] [Related]
13. Added value of [
Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
[TBL] [Abstract][Full Text] [Related]
14. The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers.
Haidar M; Shamseddine A; Panagiotidis E; Jreige M; Mukherji D; Assi R; Abousaid R; Ibrahim T; Haddad MM; Vinjamuri S
Nucl Med Commun; 2017 Feb; 38(2):170-177. PubMed ID: 27922538
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
[TBL] [Abstract][Full Text] [Related]
16. PET/CT With 68Ga-DOTA-TATE for Diagnosis of Neuroendocrine: Differentiation in Patients With Castrate-Resistant Prostate Cancer.
Gofrit ON; Frank S; Meirovitz A; Nechushtan H; Orevi M
Clin Nucl Med; 2017 Jan; 42(1):1-6. PubMed ID: 27775942
[TBL] [Abstract][Full Text] [Related]
17. Preoperative
Norlén O; Montan H; Hellman P; Stålberg P; Sundin A
World J Surg; 2018 Feb; 42(2):498-505. PubMed ID: 29159606
[TBL] [Abstract][Full Text] [Related]
18. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
Abdulrezzak U; Kurt YK; Kula M; Tutus A
Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.
Etchebehere EC; de Oliveira Santos A; Gumz B; Vicente A; Hoff PG; Corradi G; Ichiki WA; de Almeida Filho JG; Cantoni S; Camargo EE; Costa FP
J Nucl Med; 2014 Oct; 55(10):1598-604. PubMed ID: 25168627
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
